REG - Oxford Biomedica PLC - Expanded agreement with Cabaletta Bio

Oxford BioMedicaAnnouncement

22/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230822:nRSV9925Ja&default-theme=true

RNS Number : 9925J  Oxford Biomedica PLC  22 August 2023

 

 

 

Oxford Biomedica expands agreement with Cabaletta Bio; adding new viral vector
programme for CD19-CAR T therapies

 

Oxford, UK - 22 August 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO,
today announces that it has expanded its License and Supply Agreement ("LSA")
with Cabaletta Bio, Inc. (Nasdaq: CABA) ("Cabaletta Bio"), a
Philadelphia-based clinical-stage biotechnology company focused on developing
and launching the first curative targeted cell therapies for patients with
autoimmune diseases. This follows on from the LSA announced in January 2022
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1540929)
and adds CD19 as a new target.

Oxford Biomedica initially licensed its LentiVector® platform to Cabaletta
Bio for their lead product candidate, DSG3-CAART. The agreement has now been
extended to grant a non-exclusive license to Cabaletta under Oxford
Biomedica's LentiVector® platform IP for their CAR-T programme, CABA-201, a
4-1BB-containing fully human CD19-CAR T cell investigational therapy.
Cabaletta Bio has received two IND clearances to date for CABA-201 and plans
to initiate a Phase 1/2 clinical trial for patients with systemic lupus
erythematosus and lupus nephritis and a separate Phase 1/2 clinical trial for
patients with myositis.

Under the terms of the expanded agreement, Oxford Biomedica will receive an
undisclosed upfront payment, as well as additional payments relating to the
development and manufacture of lentiviral vectors for use in clinical trials.
The Company will also receive certain development and regulatory milestone
payments and an undisclosed royalty on net sales of products that utilise the
Company's LentiVector® platform.

 

Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica,
commented: "The expansion of our partnership with Cabaletta Bio stands as a
testament to Oxford Biomedica's unwavering commitment to quality and
innovation. As a world-leading CDMO with expertise across all key viral vector
types, we are committed to enabling our biopharma customers to discover and
deliver transformative therapies. We're excited to continue our work with
Cabaletta and help them deliver accessible cures for patients with severe
autoimmune disease."

 

Gwendolyn Binder, Ph.D., President, Science and Technology, Cabaletta Bio,
commented: "We are delighted to be expanding our agreement with Oxford
Biomedica, who have demonstrated their ability to provide quality products and
services since the beginning of our partnership. Their commitment to quality
and innovation has assisted us in increasing efficiencies and we look forward
to broadening this relationship as we prepare for commercial readiness with
our lead product candidate, CABA-201."

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc:

 

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

 

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at
www.oxb.com (https://www.oxb.com/) , www.oxbsolutions.com
(https://oxbsolutions.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGZRGMMGFZZ